Multiple Sclerosis, Relapsing-Remitting
Conditions
Keywords
Inflammation, IFN-beta, Autoimmunity, Gene regulation
Brief summary
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS). These studies have been performed mostly on a small scale and on whole blood mononuclear cells (PBMC). In a number of cases, RRMS progresses to a severe secondary neurodegenerative form. In this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.
Detailed description
SEP-MIR is a prospective, single-center, descriptive study. Participants will be recruited among adult patients with RRMS coming for a follow-up consultation in the Neurology Department, Nervous System Diseases Pole, at the hôpital Pitié - Salpêtrière (Paris). As this is a descriptive study, the recruitment of 20 participants (10 patients with relapsing-remitting MS and 10 patients with relapsing-remitting MS) should meet the objectives of this study. A 50 ml blood sample will be obtained from each participant and several clinical data regarding their pathology will be collected.
Interventions
GENETIC50 ml blodd sampling
50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
Sponsors
Höpital La Pitié-Salpêtrière
Institut Pasteur
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
20 untreated RRMS patients divided into 2 groups: 10 RRMS in relapsing phase 10 RRMS in relapse.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Caucasian population * Female and male individuals with an f/m ratio of 2-4/1 * Individuals with RRMS according to the 2010 McDonald criteria for less than 15 years, with EDSS 1-6, in remission or relapse * Participant's condition compatible with a maximum of 50 ml of blood collection * Persons affiliated with a social security plan.
Exclusion criteria
* MS treatment with steroidal anti-inflammatory drugs, immunomodulators or immunosuppressants within 2 months prior to blood collection * Persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than MS * Pregnant or lactating women * Be under guardianship, * Be deprived of liberty by judicial or administrative decision, or be under legal protection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| microRNA expression profiles in immune cell populations from RRMS patients | 2 years | RNAseq and/or Nanostring sequencing of PBMCs from RRMS patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| microRNA expression profiles in unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients | 2 years | RNAseq and/or Nanostring sequencing of unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients |
| microRNA expression profiles in monocytes from RRMS patients | 2 years | RNAseq and/or Nanostring sequencing of monocytes from RRMS patients |
Countries
France
Contacts
Primary ContactFrédérique Michel, PhD
Outcome results
None listed